{"protocolSection": {"identificationModule": {"nctId": "NCT00233480", "orgStudyIdInfo": {"id": "UCLA IRB #04-12-007-01"}, "secondaryIdInfos": [{"id": "1K23HL085097-01A1", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1K23HL085097-01A1"}], "organization": {"fullName": "University of California, Los Angeles", "class": "OTHER"}, "briefTitle": "Statin Therapy in Heart Failure: Potential Mechanisms of Benefit", "officialTitle": "A Double-blind Randomized, Placebo-Controlled, Single-Center Study to Assess the Impact of Statins on the Autonomic Nervous System and Cardiac Structure/Function in Non-Ischemic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2020-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-08"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-10-04", "studyFirstSubmitQcDate": "2005-10-04", "studyFirstPostDateStruct": {"date": "2005-10-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-04-01", "resultsFirstSubmitQcDate": "2020-03-06", "resultsFirstPostDateStruct": {"date": "2020-03-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-03-06", "lastUpdatePostDateStruct": {"date": "2020-03-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Tamara Horwich", "investigatorTitle": "Tamara Horwich, MD, MS", "investigatorAffiliation": "University of California, Los Angeles"}, "leadSponsor": {"name": "University of California, Los Angeles", "class": "OTHER"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}, {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The goal of the investigators' study is to further understand the potentially beneficial effects of statin therapy in patients with heart failure. It is hypothesized that statins will 1) increase the heart's pumping ability 2) improve functioning of the sympathetic nervous system and 3) decrease immune activation in heart failure.", "detailedDescription": "Recent evidence suggests that HMG-Coenzyme A (statin) therapy may be associated with improved survival in both ischemic and non-ischemic heart failure (HF). Large, randomized outcome studies of statins in HF are currently underway, but these trials will not address underlying mechanisms. The aim of the study is to investigate statins' potentially beneficial mechanisms of action in HF, focusing on: 1) sympathetic nervous system activation and 2) myocardial remodeling, and 3) immune activation in heart failure.\n\nFifty patients with systolic HF of non-ischemic etiology from a single center will be randomized in a double-blinded fashion to 3 months of atorvastatin 10mg QD (25 subjects) vs matching placebo QD (25 subjects). The following exams will be performed at baseline (pre-treatment) and at end of study (post-treatment): sympathetic microneurography, echocardiography, and peripheral blood chemokine analysis. Sympathetic microneurography at the peroneal nerve will directly quantify changes in sympathetic nerve activity (bursts/minute). Echocardiography (with the addition of MRI in a subset of subjects without pacemakers or implantable defibrillators) will be used to track changes in cardiac structure and function; indices of remodeling will include measurement of left ventricular mass index, left ventricular volume indices, left ventricular ejection fraction, and subendocardial scar quantification (MRI only). Immune activation will be characterized by circulating cytokines and chemokines. Additionally, quantification of established cardiac biomarkers (cardiac troponin, B-type natriuretic peptide, and C-reactive Protein), Holter monitor/heart rate variability studies, and quality of life and global clinical assessment will be performed pre- and post- treatment.\n\nNeither sympathetic microneurography nor MRI have been previously utilized to assess statins' effects in humans with HF. The impact of statin therapy on inflammatory chemokine activation in HF also has not been studied. The knowledge gained from our proposed investigations may serve as a basis for understanding how statin therapy has potential to improve clinical outcomes in HF, and may ultimately lead to new therapeutic strategies for HF."}, "conditionsModule": {"conditions": ["Heart Failure, Congestive"], "keywords": ["Randomized Controlled Trial", "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "Sympathetic Nervous System", "Ventricular Remodeling", "Chemokines"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 27, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "active treatment", "type": "EXPERIMENTAL", "description": "atorvastatin 10mg QD x 3 months", "interventionNames": ["Drug: atorvastatin"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "matched placebo QD x 3 months", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "atorvastatin", "description": "atorvastatin 10mg PO QD", "armGroupLabels": ["active treatment"], "otherNames": ["lipitor"]}, {"type": "DRUG", "name": "placebo", "description": "matched placebo Qd x 3 months", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "LVEF (Left Ventricular Ejection Fraction)", "description": "Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).", "timeFrame": "baseline and three months"}, {"measure": "Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)", "timeFrame": "Baseline and three months"}], "secondaryOutcomes": [{"measure": "Left Ventricular End-diastolic Dimension (LVEDD)", "description": "The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System", "timeFrame": "Baseline and three months"}, {"measure": "Cardiac Biomarker Level BNP", "description": "B-type natriuretic peptide, measured pg/mL at baseline and post-treatment", "timeFrame": "Baseline, 3 months"}, {"measure": "High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker", "timeFrame": "Baseline, Three months"}, {"measure": "Cardiac Troponin I (cTnI)", "description": "Participants with cTnI \u22650.04 ng/mL", "timeFrame": "Baseline, Three months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age\u226518 years old\n* LVEF \u2264 35%, as documented by echocardiography, radionuclide ventriculography, gated SPECT, or contrast ventriculography within past 6 months\n* Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within the last year\n* Stable doses of optimal HF medical therapy, unless documented contraindication.\n\nExclusion Criteria:\n\n* Ischemic etiology of HF, defined as the presence of at least one of the following four criteria; angiographic evidence of \\> 50% lesion in 1 or more of the 3 major epicardial vessels; history of myocardial infarction; history of revascularization procedure; evidence of significant perfusion defect in the setting of ischemic symptoms.\n* Clinical indication for statin treatment - coronary artery, cerebrovascular, or peripheral vascular disease\n* Major cardiovascular event or surgical procedure within past 8 weeks\n* LDL\\<70 mg/dL\n* HF secondary to congenital heart disease or uncorrected valvular disease\n* Treatment with statin within past 2 months\n* Pregnancy\n* Contraindication to statin: moderate liver disease, AST/ALT \\> 150 U/ L, known hypersensitivity\n* Likely to receive heart transplant within 3 months\n* Known peripheral or autonomic neuropathy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Tamara B Horwich, MD", "affiliation": "UCLA Division of Cardiology", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Ahmanson-UCLA Cardiomyopathy Center", "city": "Los Angeles", "state": "California", "zip": "90095", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}]}, "referencesModule": {"references": [{"pmid": "18433696", "type": "BACKGROUND", "citation": "Horwich TB, Middlekauff HR. Potential autonomic nervous system effects of statins in heart failure. Heart Fail Clin. 2008 Apr;4(2):163-70. doi: 10.1016/j.hfc.2008.01.004."}, {"pmid": "18001265", "type": "BACKGROUND", "citation": "Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007 Dec;8(17):3061-8. doi: 10.1517/14656566.8.17.3061."}, {"type": "RESULT", "citation": "PubMed ID 22041323"}, {"pmid": "22041323", "type": "DERIVED", "citation": "Horwich TB, Middlekauff HR, Maclellan WR, Fonarow GC. Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail. 2011 Nov;17(11):879-86. doi: 10.1016/j.cardfail.2011.07.008. Epub 2011 Sep 3."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Active Treatment", "description": "atorvastatin 10mg QD x 3 months"}, {"id": "FG001", "title": "Placebo", "description": "matched placebo QD x 3 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Underwent status II heart transplant", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Active Treatment", "description": "atorvastatin 10mg QD x 3 months"}, {"id": "BG001", "title": "Placebo", "description": "matched placebo QD x 3 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47", "spread": "14"}, {"groupId": "BG001", "value": "49", "spread": "17"}, {"groupId": "BG002", "value": "48", "spread": "15"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "LVEF (Left Ventricular Ejection Fraction)", "description": "Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent ejection fraction", "timeFrame": "baseline and three months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg QD x 3 months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo QD x 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline LVEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "24", "spread": "6"}, {"groupId": "OG001", "value": "28", "spread": "7"}]}]}, {"title": "3 month LVEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "25", "spread": "6"}, {"groupId": "OG001", "value": "24", "spread": "7"}]}]}], "analyses": [{"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.025", "statisticalMethod": "paired t test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "PRIMARY", "title": "Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)", "populationDescription": "Eighteen subjects had baseline and final sympathetic microneurographic tracings that were technically adequate for analysis. Reasons for inadequate microneurographic tracing were: 1) inability of investigators to locate sympathetic nerve on baseline or final study; or 2) inability of patient to tolerate discomfort of the procedure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bursts per minute", "timeFrame": "Baseline and three months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg daily for three months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo daily for three months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "43", "spread": "3"}, {"groupId": "OG001", "value": "39", "spread": "3"}]}]}, {"title": "Three months", "categories": [{"measurements": [{"groupId": "OG000", "value": "36", "spread": "5"}, {"groupId": "OG001", "value": "38", "spread": "3"}]}]}]}, {"type": "SECONDARY", "title": "Left Ventricular End-diastolic Dimension (LVEDD)", "description": "The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Millimeters (mm)", "timeFrame": "Baseline and three months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg daily for three months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo daily for three months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline LVEDD", "categories": [{"measurements": [{"groupId": "OG000", "value": "65", "spread": "12"}, {"groupId": "OG001", "value": "28", "spread": "7"}]}]}, {"title": "Three months LVEDD", "categories": [{"measurements": [{"groupId": "OG000", "value": "25", "spread": "6"}, {"groupId": "OG001", "value": "24", "spread": "7"}]}]}]}, {"type": "SECONDARY", "title": "Cardiac Biomarker Level BNP", "description": "B-type natriuretic peptide, measured pg/mL at baseline and post-treatment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg QD x 3 months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo QD x 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "175", "lowerLimit": "36", "upperLimit": "472"}, {"groupId": "OG001", "value": "66", "lowerLimit": "29", "upperLimit": "154"}]}]}, {"title": "Three Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "107", "lowerLimit": "34", "upperLimit": "173"}, {"groupId": "OG001", "value": "67", "lowerLimit": "21", "upperLimit": "299"}]}]}]}, {"type": "SECONDARY", "title": "High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "mg/L", "timeFrame": "Baseline, Three months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg daily for three months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo daily for three months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "lowerLimit": "0.6", "upperLimit": "4.4"}, {"groupId": "OG001", "value": "1.9", "lowerLimit": "1.0", "upperLimit": "3.0"}]}]}, {"title": "Three months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.9", "lowerLimit": ".05", "upperLimit": "5.7"}, {"groupId": "OG001", "value": "3.4", "lowerLimit": "1.1", "upperLimit": "5.9"}]}]}]}, {"type": "SECONDARY", "title": "Cardiac Troponin I (cTnI)", "description": "Participants with cTnI \u22650.04 ng/mL", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline, Three months", "groups": [{"id": "OG000", "title": "Active Treatment", "description": "atorvastatin 10mg daily for three months"}, {"id": "OG001", "title": "Placebo", "description": "matched placebo daily for three months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Three Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "3 months", "eventGroups": [{"id": "EG000", "title": "Active Treatment", "description": "atorvastatin 10mg QD x 3 months", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}, {"id": "EG001", "title": "Placebo", "description": "matched placebo QD x 3 months", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 0, "otherNumAtRisk": 13}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Tamara B Horwich, MD", "organization": "Ahmanson-UCLA Cardiomyopathy Center", "email": "thorwich@mednet.ucla.edu", "phone": "310-825-8676"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M22079", "name": "Ventricular Remodeling", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}